Interferon-γ Reduces Melanosomal Antigen Expression and Recognition of Melanoma Cells by Cytotoxic T Cells

In malignant melanoma, tumor-infiltrating lymphocytes are frequently reactive with melanosomal antigens. Achieving complete remissions by peptide therapy is frequently hampered by metastases evading immune recognition. The tumor microenvironment seems to favor reduced expression of target antigens by melanoma cells. Among candidate factors, interferon-γ (IFN-γ) (102 to 103 U/ml) suppressed expression of antigens MART-1, TRP-1, and gp100 by M14 melanoma cells as shown by immunohistology and fluorescence-activated cell sorting analysis, reducing MART-1 expression by >65%. Northern blot analysis revealed that reduced expression was regulated at the transcriptional level, demonstrating a 79% reduction in MART-1 transcript abundance after 32 hours of IFN-γ treatment. To evaluate consequences of IFN-γ exposure for immune recognition, MART-1-responsive T cells were reacted with pretreated HLA-matched melanoma cells. Cytotoxicity was reduced up to 78% by IFN-γ pretreatment, and was restored by addition of MART-1 peptide AAGIGILTV for 2 hours. Examination of melanoma lesions by quantitative reverse transcriptase-polymerase chain reaction revealed up to 188-fold more abundant IFN-γ transcripts when compared to control skin. Laser capture microdissection and immunohistology localized most IFN-γ-producing T cells to the tumor stroma. Reduced MART-1 expression was frequently observed in adjacent tumor cells. Consequently, IFN-γ may enhance inflammatory responses yet hamper effective recognition of melanoma cells.

[1]  J. Nemunaitis,et al.  Induction of melanoma-associated antigen systemic immunity upon intratumoral delivery of interferon-γ retroviral vector in melanoma patients , 2000, Cancer Gene Therapy.

[2]  E. Danen,et al.  Cytokine‐mediated modulation of integrin, ICAM‐1 and CD44 expression on human uveal melanoma cells in vitro , 1995, Melanoma research.

[3]  S. Rosenberg,et al.  Developing recombinant and synthetic vaccines for the treatment of melanoma. , 1999, Current opinion in oncology.

[4]  A. Houghton,et al.  A melanosomal membrane protein is a cell surface target for melanoma therapy. , 1996, Clinical cancer research : an official journal of the American Association for Cancer Research.

[5]  F. Marincola,et al.  Loss of HLA class I antigens by melanoma cells: molecular mechanisms, functional significance and clinical relevance. , 1995, Immunology today.

[6]  A. Palucka,et al.  Cross-Priming of Naive Cd8 T Cells against Melanoma Antigens Using Dendritic Cells Loaded with Killed Allogeneic Melanoma Cells , 2000, The Journal of experimental medicine.

[7]  R. Day,et al.  Analysis of therapeutic and immunologic effects of R24 anti‐GD3 monoclonal antibody in 37 patients with metastatic melanoma , 2000, Cancer.

[8]  D. Galloway,et al.  Generation of a human melanocyte cell line by introduction of HPV16 E6 and E7 genes , 1997, In Vitro Cellular & Developmental Biology - Animal.

[9]  P. Romero,et al.  Analysis of MAGE-3-specific cytolytic T lymphocytes in human leukocyte antigen-A2 melanoma patients. , 1997, Cancer research.

[10]  C. Figdor,et al.  Generation of antimelanoma cytotoxic T lymphocytes from healthy donors after presentation of melanoma-associated antigen-derived epitopes by dendritic cells in vitro. , 1995, Cancer research.

[11]  W. Mooi,et al.  Micro‐anatomy related antigen expression in melanocytic lesions , 2000, The Journal of pathology.

[12]  R. Saxton,et al.  Establishment of an ascitic human melanoma cell line that metastasizes to lung and liver in nude mice , 2004, Journal of Cancer Research and Clinical Oncology.

[13]  E. Wang,et al.  Development and characterization of melanoma cell lines established by fine-needle aspiration biopsy: advances in the monitoring of patients with metastatic melanoma. , 1999, Cancer detection and prevention.

[14]  I. Shih,et al.  Interactions of melanocytes and melanoma cells with the microenvironment. , 1994, Pigment cell research.

[15]  G. Duigou,et al.  Regulation of class II MHC gene expression by interferons: insights into the mechanism of action of interferon (review). , 1988, Anticancer research.

[16]  S. Rosenberg,et al.  Regression of established pulmonary metastases and subcutaneous tumor mediated by the systemic administration of high-dose recombinant interleukin 2 , 1985, The Journal of experimental medicine.

[17]  H. Pircher,et al.  Immunotherapy with dendritic cells and tumor major histocompatibility complex class I-derived peptides requires a high density of antigen on tumor cells. , 2000, Cancer research.

[18]  A. Becker,et al.  Practical suggestions for successful immunoenzyme double-staining experiments , 2004, The Histochemical Journal.

[19]  A. Chang,et al.  Immunogenetic therapy of human melanoma utilizing autologous tumor cells transduced to secrete granulocyte-macrophage colony-stimulating factor. , 2000, Human gene therapy.

[20]  T. Luger,et al.  α-Melanocyte-Stimulating Hormone as a Mediator of Tolerance Induction , 2000, Pathobiology.

[21]  R. Halaban,et al.  Aberrant retention of tyrosinase in the endoplasmic reticulum mediates accelerated degradation of the enzyme and contributes to the dedifferentiated phenotype of amelanotic melanoma cells. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[22]  V. Hearing,et al.  Melanosomal proteins as melanoma-specific immune targets. , 1997, Melanoma research.

[23]  J. Zeuthen,et al.  Differential modulation by interferon γ of the sensitivity of human melanoma cells to cytolytic T cell clones that recognize differentiation or progression antigens , 1996, Cancer Immunology, Immunotherapy.

[24]  D. Hicklin,et al.  Down-regulation of HLA class I antigen-processing molecules in malignant melanoma: association with disease progression. , 1999, The American journal of pathology.

[25]  R. Dutton,et al.  Immunopotentiating role of IFN-gamma in early and late stages of type 1 CD8 effector cell-mediated tumor rejection. , 2001, Clinical immunology.

[26]  William E Grizzle,et al.  The p44S10 locus, encoding a subunit of the proteasome regulatory particle, is amplified during progression of cutaneous malignant melanoma , 2000, Oncogene.

[27]  S. Rosenberg,et al.  Identification of MART-1-specific T-cell receptors: T cells utilizing distinct T-cell receptor variable and joining regions recognize the same tumor epitope. , 1994, Cancer research.

[28]  U. Boehm,et al.  Cellular responses to interferon-gamma. , 1997, Annual review of immunology.

[29]  S. Steinberg,et al.  Threshold levels of gene expression of the melanoma antigen gp100 correlate with tumor cell recognition by cytotoxic T lymphocytes , 2000, International journal of cancer.

[30]  S. Carrel,et al.  Recombinant interferon‐γ can induce the expression of HLA‐DR and ‐DC on DR‐negative melanoma cells and enhance the expression of HLA‐ABC and tumor‐associated antigens , 1985 .

[31]  E. Wang,et al.  Functional analysis of antigen-specific T lymphocytes by serial measurement of gene expression in peripheral blood mononuclear cells and tumor specimens. , 1999, Journal of immunology.

[32]  Mark M. Davis,et al.  Melanocyte Destruction after Antigen-Specific Immunotherapy of Melanoma , 2000, The Journal of experimental medicine.

[33]  W. Westerhof,et al.  Local Immune Response in Skin of Generalized Vitiligo Patients , 2000, Laboratory Investigation.

[34]  C. Figdor,et al.  Identification of a novel peptide derived from the melanocyte‐specific gp100 antigen as the dominant epitope recognized by an HLA‐A2.1‐restricted anti‐melanoma CTL line , 1995, International journal of cancer.

[35]  M. Probst-Kepper,et al.  Processing of some antigens by the standard proteasome but not by the immunoproteasome results in poor presentation by dendritic cells. , 2000, Immunity.

[36]  G. Beatty,et al.  IFN-γ Can Promote Tumor Evasion of the Immune System In Vivo by Down-Regulating Cellular Levels of an Endogenous Tumor Antigen1 , 2000, The Journal of Immunology.

[37]  D. Hunt,et al.  Melanomas with concordant loss of multiple melanocytic differentiation proteins: immune escape that may be overcome by targeting unique or undefined antigens , 2000, Cancer Immunology, Immunotherapy.